Biomarkers Predicting Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer

Overview

Journal Am J Clin Pathol

Publisher Oxford University Press

Specialty Pathology

Date 2016 Jun 15

PMID 27298399

Citations 36

Authors

Xiaoxian Bill Li

Uma Krishnamurti

Shristi Bhattarai

Sergey Klimov

Michelle D Reid

Ruth ORegan

Ritu Aneja

Affiliations

Soon will be listed here.

Abstract

Objectives: Recent studies have shown strong correlation of pathologic complete response (pCR) to neoadjuvant chemotherapy with survival and prognosis in breast cancers.

Methods: Clinical data from 237 breast cancer patients who received neoadjuvant chemotherapy between 2012 and 2014 were reviewed. Correlations were sought between pCR and estrogen receptor (ER), progesterone receptor (PR), and HER2 status; Nottingham and nuclear grades; tumor tubule formation; mitotic score; Ki67 index; and tumoral and stromal lymphocytic infiltration (TLI and SLI, respectively).

Results: Of the 237 cases, 104 (43.9%) achieved pCR. The HER2+ and triple negative breast cancer (TNBC) subtypes had higher pCR rates compared with the luminal subtype (ER+ or PR+ and HER2-). ER and PR negativity, HER2 positivity, Nottingham grade 3, increased TLI and SLI, high mitotic count and Ki67 score correlated significantly with pCR in the overall cohort. TLI and SLI correlated significantly with pCR in the HER2+ and TNBC subtypes in multivariate analysis, whereas no biomarkers correlated with pCR in the luminal subtype.

Conclusions: In addition to the pathologic parameters and biomarkers already routinely assessed, evaluation of TLI and SLI may help to better select patients with HER2+ and TNBC for neoadjuvant chemotherapy.

Citing Articles

Pathologic response rates in HER2-low versus HER2-zero early breast cancer patients receiving neoadjuvant therapy: a systematic review and meta-analysis.

de Moraes F, de Castro Ribeiro C, Pessoa F, Chaves J, de Souza A, Di Felipe Avila Alcantara D Breast Cancer Res. 2025; 27(1):39.

PMID: 40089780 DOI: 10.1186/s13058-025-01989-9.

Cell cycle traverse rate predicts long-term outcomes in a multi-institutional cohort of patients with triple-negative breast cancer.

Bhattarai S, Rupji M, Chao H, Xu Q, Saini G, Rida P BJC Rep. 2024; 2(1):87.

PMID: 39537757 PMC: 11561184. DOI: 10.1038/s44276-024-00097-z.

Imaging evaluation focused on microstructural tissue changes using tensor-valued diffusion encoding in breast cancers after neoadjuvant chemotherapy: is it a promising way forward?.

Cho E, Baek H, Szczepankiewicz F, An H, Jung E Gland Surg. 2024; 13(8):1387-1399.

PMID: 39282030 PMC: 11399009. DOI: 10.21037/gs-24-124.

Racial/Ethnic Disparities in Pathologic Complete Response and Overall Survival in Patients With Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy.

Woriax H, Thomas S, Plichta J, Rosenberger L, van den Bruele A, Chiba A J Clin Oncol. 2024; 42(14):1635-1645.

PMID: 38394476 PMC: 11095870. DOI: 10.1200/JCO.23.01199.

High tumor infiltrating lymphocytes are significantly associated with pathological complete response in triple negative breast cancer treated with neoadjuvant KEYNOTE-522 chemoimmunotherapy.

Wood S, Gao Y, Lee J, Chen J, Wang Q, Meisel J Breast Cancer Res Treat. 2024; 205(1):193-199.

PMID: 38286889 DOI: 10.1007/s10549-023-07233-2.